Dr Ngozwana has over 20 years of experience in the Pharmaceutical and Healthcare space. His earlier role was that of President of Serenus Biotherapeutics, a company he co-founded. He is the current Chairman of Biovac, a South African vaccine manufacturer (and a Public Private Partnership).
He is an international expert on the African Pharmaceutical industry, who has served as a consultant to the World Health Organization (WHO), United Nations Industrial Development Organization (UNIDO), the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the United States Pharmacopeia Convention (USP) among others. As the International lead consultant for UNIDO, Dr Ngozwana co-authored the Pharmaceutical Manufacturing Plan for Africa that was adopted by the African Union heads of state and government in 2012.
The plan was the output of the extensive research and analytical work he conducted on the African pharmaceutical industry. His recent UN assignment was as part of an expert team of three appointed to develop the Ethiopian Pharmaceutical Sector Strategy and Action Plan. This document was adopted by the Ethiopian government as a blueprint for developing the Ethiopian sector; and is now incorporated into the Ethiopian Growth and Transformation Plan II.
Prior to his consulting career, he worked for Cipla Medpro as its Deputy Chief Executive Officer. He is passionate about the development of the African pharmaceutical industry; access to quality assured medicines on the continent and has made significant contributions in developing the Industry. Some of his contributions include the following: He is the chairman of the board of Directors of the Biovac Initiative (a South African Vaccine manufacturer – and a Public Private Partnership).
He served as Chairman of the National Association of Pharmaceutical Manufacturers of South Africa, and led the NAPM into the International Generic Medicines Alliance (IGPA). He is the founding chairman of the Southern African Generic Medicines Association; and founding member of the Federation of African Pharmaceutical Manufacturers Association (FAPMA); both of which he continues to serve as a board member. He is a former member of the Centre for Scientific and Industrial Research’s Biosciences Research Advisory Panel.
As part of a key group of African Pharmaceutical executives, he has been intimately involved in efforts to lobby and engage multilateral organizations and the international global health community on behalf of African pharma, including:
- UN Secretary-Generals High-Level Panel on Access to Medicines – Thought Leaders Forum. Johannesburg, South Africa. 16 March 2016. “Perspectives on local pharmaceutical production in Africa”.
- UNAIDS Programme Coordinating Board Meeting, Geneva. Switzerland. 28 October 2015. “The Power of Partnerships for Implementation, Innovation and Equity’’.
- World Health Summit, Berlin, Germany. 13 October 2015. “Ensuring Access to Affordable Essential Medicines and Health”.
- United Nations Industrial Development Organization (UNIDO), Industrial Development Board Meeting, Vienna, Austria. November 24th, 2010. “Challenges and Potential of local pharmaceutical production in Southern Africa: role & possible contributions by a regional business membership organization”.
- African Leaders Malaria Alliance. Nairobi Kenya, May 31st, 2011. “Consultation on Challenges Faced by Africa-based Manufacturers of Pharmaceuticals and other health products”.
As a thought leader, he has been invited to share his extensive knowledge on various topics on African pharma at leading local and international pharmaceutical and public healthcare conferences and key stakeholder engagement platforms. He brings a nuanced understanding of the African and global pharmaceutical industry, and a global network of contacts with key stakeholders including national medicine regulators, procurement boards and pharmaceutical manufacturers; and within international pharma companies and across various global public health organizations (e.g. WHO, USP, UNAIDS, Global Fund, UNITAID, Gates Foundation, African Medicines Regulatory Harmonization initiative etc.) at senior executive level.
Dr Ngozwana holds qualifications in Medicine, Medical Pharmacology and Business Administration.